Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Designing Memorable Workshops: A Workshop for Presenters and Teachers of Addiction Medicine (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This session will use a combination of brief didactic teaching and a variety of interactive and participatory methods. We will introduce learners to the steps of workshop design and evaluation.

    People remember about 20% of what they hear, 30% of what they see and 50% of what they see and hear. (Labonte, 1972) Most importantly, people remember how you made them feel. Therefore, when we teach we need to make it memorable by making the learning transformational. We need to create learning environments where in addition to cognitive learning, we promote affective and psychomotor learning ( Bloom's taxonomy, 1964). Workshops are brief small group learning activities which allow learners the opportunity to participate in problem solving to facilitate knowledge acquisition, attitudinal change or skill development. When properly designed based on adult and experiential learning principles it can be a time and cost efficient method of instruction. Moreover, it makes learning fun! This facilitated small group session will use a combination of brief didactic teaching and a variety of interactive and participatory methods. We will introduce learners to the steps of workshop design and evaluation. In addition we will have small groups co-create the development of an interactive exercise based on the competencies for Addiction Medicine. Techniques to enhance interaction and audience participation such as "pair and share" will be practiced. The workshop will conclude with a large group debrief and commitment by participants to submit a workshop for consideration at the next ASAM annual conference.

    Peter Selby

    MBBS, CCFP, FCFP, DFASAM

    Peter Selby MD is the Director of Medical Education and a Clinician Scientist at the Centre for Addiction and Mental Health. He is a Professor in the Departments of Family and Community Medicine, Psychiatry, and the Dalla Lana School of Public Health at the University of Toronto. He is also a Clinician Scientist in the Department of Family and Community Medicine. Dr. Selby is the Executive Director and creator of the TEACH project; a continuing education certificate program in Applied Counselling for Health with a focus on smoking cessation, through the University of Toronto. Dr. Selby’s research, as a Principal Investigator at the Ontario Tobacco Research Unit, includes smoking cessation especially in smokers with co-morbid conditions. As the Principal Investigator of the STOP Study, he investigates the effectiveness of NRT and counselling in different types of intervention settings. He is also the PI of CANADAPTT- a unique Canadian Smoking Cessation Guideline development and dissemination project. Dr. Selby also continues his clinical research with pregnant women who use substances and is the PI of a knowledge translation program (PREGNETS) to increase the adoption of evidence-based interventions with pregnant smokers. 

    He has received grant funding totaling over 80 million dollars from CIHR, NIH, and Ministry of Health and has published 130 peer reviewed publications. He has published 5 books (including 4 edited), is the author of 30 book chapters, and 32 research reports prepared for the government. He is the Co-Chair for the Ministry of Health Cessation Task force and the Chair of the Canadian Centre on Substance Abuse National Task Force on Treatment for Prescription Drug Misuse. Dr. Selby mentors Fellows in Addiction Medicine and Addiction Psychiatry, junior investigators and medical students. Dr. Selby a sought after speaker for various topics including addictive disorders, motivational interviewing, and health behavior change.

    Miriam S. Komaromy

    MD, FACP, DFASAM

    Dr. Komaromy is an Associate Professor of Medicine and Associate Director of the ECHO Institute (echo.unm.edu), which is a program based at the University of New Mexico Health Sciences Center that is aimed at expanding access to treatment for traditionally underserved populations. She is Director for the Integrated Addictions and Psychiatry teleECHO program, which engages and supports primary care teams in treating addiction and behavioral health disorders. Through this program she has trained more than 500 physicians to provide buprenorphine treatment for opioid use disorder. She is board certified in Addiction Medicine through the American Society of Addiction Medicine. She serves on several national committees focused on addiction medicine.. She practices addiction medicine in a primary care outpatient clinic setting, and is a newly elected Board Member for the American Society of Addiction Medicine (ASAM). She has served as medical director for the NM State Addiction Treatment Hospital. She lectures nationally on clinical and health policy issues related to integration of addiction treatment into the primary care setting, and on the use of the ECHO model to train primary care providers to treat common, complex diseases such as behavioral health and substance use disorders. 

    Michael Fingerhood

    MD, FACP

    Dr. Michael Fingerhood is an Associate Professor of Medicine at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance abuse treatment with primary medical care, including care for HIV and hepatitis C.

  • Implementing Tobacco-Free Policies in Residential Addiction Treatment Settings (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This workshop shares the experiences of three residential addiction treatment center implementing tobacco-free policies. We will review the epidemiology of tobacco use disorders with respect to patients with other substance use disorders. We will have small group discussion to facilitate how each workshop participant could implement tobacco-free policies at their respective programs.

    Goals:

    Discuss the prevalence of nicotine addiction and barriers to treatment among people in addiction treatment settings
    Review the data and outcomes of 3 residential treatment centers that transitioned to being tobacco-free 
    Each participant will be able to develop a Strengths, Weakness, Opportunities and Threats (SWOT) analysis, Stage of Change Analysis 

    Description:
    Historically, residential level substance use disorder treatment centers have allowed patients to continue to use tobacco on site and have incorporated only limited treatment for tobacco dependence into their programs. Beliefs associated with this failure to address tobacco dependence have included fears that individuals with tobacco use disorders would lose access to viable treatment because they would refuse to abstain, that treatment center census levels and completion rates could decline or that staff culture would not support such a change. Due to rising concerns about the number of patients and staff who were exposed to second hand smoke, the number of patients who were increasing their tobacco use during treatment, and the number of missed opportunities to treat tobacco dependence, three residential addiction treatment centers transitioned to being tobacco-free facilities between 2013 and 2015. This workshop will present data on how this change in policy had a positive effect on patient admissions and census data and did not reduce access to care for tobacco users. This workshop will then outline key partnerships during this transition, the steps followed during the transition, and lessons learned during this transition. We will conclude with interactive exercises that will allow participants to develop action plans for addressing tobacco use disorders within their own treatment settings.

    Contents and Methods:
    Powerpoint format for didactic review, presentation of outcomes and outlining key steps in the tobacco-free transition will be used for approximately one-third of the session. Active audience participation during the first third will be encouraged by the use of frequent questions and interaction with participants. The workshop will break into 3 smaller groups to develop individualized plans for the second third of the presentation. The last third of the workshop will be spent in large group discussion regarding potential obstacles to implementation of individualized plans.

    Laura Martin

    MD, FASAM

    Laura F. Martin, M.D. is an Associate Professor of Psychiatry at the University of Colorado School of Medicine.  She is a board certified psychiatrist and addiction medicine specialist.  She has been recognized as a member of the American College of Psychiatrists, a Fellow of the American Society of Addiction Medicine, and a Distinguished Fellow of the American Psychiatric Association.   Her professional roles include serving as the Medical Director of the Center for Dependence, Addiction and Rehabilitation (CeDAR), Program Director of the Addiction Medicine Fellowship at the University of Colorado School of Medicine, and as President of the Colorado Society of Addiction Medicine.  She regularly works with individuals with both substance use disorders and other behavioral health disorders to improve their physical and mental health and has published peer reviewed research and clinical reviews regarding this work. 

    Brian Coon

    MA, LCAS, CCS, MAC

    Brian Coon, MA, LCAS, CCS, MAC is Pavillon's Director of Clinical Programs. His duties include direction of the evaluation and treatment of the medical, legal, and other professionals served at Pavillon, development of organization-wide clinical programing, clinical staff education, internal and external training, outcome evaluation, research and publication.  Brian leads pre-admission clinical coordination and approval for admissions to Pavillon's residential programs.  Furthermore, Brian is responsible for development and integration of the use of technology within Pavillon's clinical services.  He received both his undergraduate degree in psychology and his master's degree in community-clinical psychology from Bradley University in Peoria, Illinois.  He began his full-time clinical work during his graduate internship in 1988.  Since that time he has worked in addressing co-occurring substance use and mental health disorders in roles ranging from clinician to clinical supervisor and manager of multiple treatment programs.  He is a Licensed Clinical Addictions Specialist, Certified Clinical Supervisor, and nationally credentialed as a Master Addiction Counselor.  His clinical background is in cognitive-behavioral psychology and evidence-based treatment of co-occurring disorders in various residential and outpatient modalities and levels of care.

    Jonathan C. Lee

    MD

    Jonathan C. Lee, MD, is currently the President-Elect for the Virginia Society of Addiction Medicine (VASAM).  He has served as the Secretary/Treasurer for VASAM from 2014 through 2016.  He has Co-Chaired the CME program for VASAM meetings in 2015 and 2016.  He organized an educational meeting for VASAM members in 2014 to revive chapter activities.  He represented VASAM at the ASAM Annual Meeting in 2016 and received our 20th Anniversary plaque.  He has collaborated with addiction medicine providers to work with the Virginia Department of Health and the Governor's Task Force and SAMHSA to address the opioid epidemic.  Dr. Lee is currently enrolled in an MBA program at the College of William & Mary.  He plans to utilize his organizational and management skills to lead VASAM in advocating for access to affordable and effective treatment for patients with addiction.

    Since 2010, Dr. Lee has served as Associate Medical Director at the Farley Center in Williamsburg Place to provide addiction treatment for the general adult population and professionals.  In 2015, Dr. Lee worked with the various department heads at the Farley Center to transition to a tobacco free program.  Dr. Lee is board certified in addiction medicine, internal medicine, and general psychiatry.  He completed training in combined internal medicine & psychiatry at Duke University Medical Center.  He graduated from the University of Virginia School of Medicine.  He completed his bachelors of science with a minor in music at the Massachusetts Institute of Technology.

  • A New Landscape in Transitional Maintenance of Certification (Tmoc) for Addiction Medicine (1 CME)

    Contains 3 Component(s), Includes Credits

    Presenters will demonstrate how the Tmoc program will serve not only as a tool to assist addiction medicine certified physicians in meeting their Tmoc requirements, but also serve as a mechanism that will allow for continuous professional development during the ABMS transitional period. In addition, attendees will have an opportunity to discuss the current Tmoc Program requirements and the new Practice Performance Assessment portion of the Tmoc program. It is an opportunity for addiction medicine certified physicians to understand the breath of the transitional period.

    The landscape of Maintenance of Certification (MOC) programs is rapidly changing though out medicine as well as addiction medicine. Addiction medicine certified physicians are becoming aware of the importance ABAM's Transitional Maintenance of Certification (Tmoc) program. Tmoc refers to the MOC process during the ABMS Practice Pathway period. Tmoc participation will allow diplomates to sustain their active ABAM credential during the transitional period and Practice Pathway into ABMS certification. Completion of ABAM Tmoc requirements will be an eligibility requirement for addiction medicine certified physicians who wish to utilize the qualifying pathway, which the American Board of Preventive Medicine (ABPM) is expected to offer to ABAM diplomates. This is consistent with past new subspecialty fields. In addition, the concept of Practice Performance Assessment (Part IV MOC) for addiction medicine will be introduced and roughly parallels Part IV of other boards. By attending this workshop, participants will gain a better understanding of the addiction medicine Tmoc program and the importance of participation. In addition, participants will learn how participation in this program may help them prepare for the American Board of Medical Specialties (ABMS), ABPM administrated certification examination. At the conclusion of this presentation, physicians will have gained a better understanding regarding of their current certification status and how it relates to participation in the Tmoc program.

    Lia Bennett

    MPH

    Lia Bennett is an independent consultant serving as the Director of Maintenance of Certification for the American Board of Addiction. She was a quality improvement program coordinator for the American College of Physicians and brings to ABAM, over 10 years of experience developing and managing MOC compliant programs. She has worked in the field of internal medicine conducting continuing medical education research in the areas of adult immunization, cardiovascular risk and diabetes. Ms. Bennett received her Masters of Public Health with a graduate certificate in Integrative Health. She strives to provide superior guidance to ABAM Diplomates.

    Robert Sokol

    MD

    Dr. Robert J. Sokol currently serves as a Distinguished Professor of Obstetrics and Gynecology and Physiology and the John M. Malone, Jr., M.D., Endowed Chair and Director of the C.S. Mott Center for Human Growth and Development at Wayne State University in Detroit, Mich. Dr. Sokol graduated with the highest distinction in philosophy and from medical school with honors from the University of Rochester in New York. After residency training at Washington University/Barnes Hospital in St. Louis, Mo., and after serving as Dr. Willard Allen's last executive Chief Resident, he served in the Air Force as a Major and then completed a fellowship at Maternal-Fetal Medicine, as well as joining the faculty, first at the University of Rochester and then at Metrohealth/Case Western Reserve in Cleveland. He worked his way up to Professor and Director of the Perinatal Clinical Research Center. Recruited as Chair of the Department of Obstetrics and Gynecology at the Wayne State University School of Medicine/Detroit Medical Center in 1983, he served as Dean and Senior Vice President for Medical Affairs from 1988 until 1999. Dr. Sokol is an internationally recognized expert in the area of fetal alcohol spectrum disorders. In 1986, he established and directed the National Institutes of Health-funded WSU Fetal Alcohol Research Center, the only center of its kind in the country at the time. He is currently focused on risk detection and prevention methodology. He is Project Manager II for services in support of the Perinatology Research Branch of the NICHD and was the founding Chair of a University Department of Clinical and Translational Science. He has about 335 referreed papers and about 1500 total publications. He is President Elect of the American Board of Addiction Medicine.

  • Addressing Adolescent Substance Use: How to Recognize, Screen, and Communicate (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This session will feature a curriculum on addressing adolescent substance use and disorders in general medical practice, developed by a broad coalition of stakeholders with funding from the Hilton Foundation, featuring a substantial contribution by ASAM.

    This session will feature a curriculum on addressing adolescent substance use and disorders in general medical practice, developed by a broad coalition of stakeholders with funding from the Hilton Foundation, featuring a substantial contribution by ASAM. Curriculum components include: scope of the problem, adolescent risk and vulnerability, screening, assessment, communication with patients, communication with parents, monitoring by parents, specialty referral, and practitioner follow-up. The session will consist of presentation of the curriculum followed by an interactive discussion about implementation with emphasis on equipping participants to be presenters and trainers to disseminate the material to their colleagues.

    Marc J. Fishman

    MD, DFASAM

    Marc Fishman MD is board certified in addiction psychiatry and addiction medicine. A faculty member of the Johns Hopkins University School of Medicine, he is Medical Director and CEO of Maryland Treatment Centers, a regional behavioral health care provider, with inpatient and outpatient facilities for adolescents and adults. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and co-occurring disorders. He has been principal investigator or collaborator for several NIDA- and CSAT-funded projects to improve and evaluate adolescent treatment, as well as pharmacotherapy trials in adults. He is the author of numerous articles and book chapters on addiction treatment, and lectures widely on a variety of topics including adolescent treatment, youth opioid treatment, placement and treatment matching strategies. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine.

  • Developing Effective Teams for Patient-Centered Care (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    In today’s healthcare environment, data continues to support an integrated, team approach to obtaining the best patient outcomes. This session will look at how to identify community resources as well as best practices in integration and team care.

    In today’s healthcare environment, data continues to support an integrated, team approach to obtaining the best patient outcomes. This session will look at how to identify community resources as well as best practices in integration and team care.

    Becky D. Vaughn

    MSEd

    Becky Vaughn has been working in the addictions field for 35 years.  She was a member of the founding board of The Georgia Association for the Prevention and Treatment of Substance Abuse (GAPTSA) in 1992 and became their first Executive Director in 1994. Her responsibilities included training and advocacy at the local, state, and national level.  In July of 2000 GAPTSA merged with an Atlanta coalition creating The Georgia Council on Substance Abuse where she served as President and CEO until 2007.  Her work continued there as an advocate at the Legislature and catalyst in the community on issues related to prevention, treatment, recovery, homelessness, and drug courts with the goal of reducing the impact of substance use on GA communities.  Her work included passage of many bills addressing addiction solutions as well as securing budget resources.  Beginning in 2008 she took over the helm of the State Associations of Addiction Services (SAAS) as their CEO after serving on its Board since 2000.  After the merger of SAAS with the National Council for Behavioral Health, Becky served as the newly created VP for Addictions at the Council building the addiction presence and services there until 2016.  In addition to her work at the Addiction Policy Forum, her consulting focuses on public policy, training, and technical assistance to service providers and state provider associations. She has served on numerous state and federal committees and panels and speaks on the issue in a variety of settings.  Becky received her degrees from the University of Georgia and Georgia State University.  She grew up in Atlanta, but is enjoying being part of the DC community.  As a former teacher and the mother of four, she is passionate about preventing and finding solutions to the far-reaching problems caused by untreated addiction.

  • The Importance of Payer Relations: Collaboration, Evidenced-Based Treatment and Reimbursement in your Practice - A Panel Discussion (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This is enduring material has been made available free of charge by the American Society of Addiction Medicine.

    In the midst of an opioid epidemic and uncertainty with health care coverage, understanding the "how's" and "why's" payers function as they do is increasingly important. This topic is relevant to providers dedicated to evidenced-based treatment, participation in solutions, and improvement in patient outcomes. Panelists from ASAM's Payer Relations Committee will offer thoughts on the best ways to form working relationships with Managed Care Organizations, Health Plans, and Third-Party Payers. The purpose of this discussion is to conceptualize what payers do, to whom they are accountable, and the frameworks within which they must function. The ultimate goal is to provide perspective and emphasize the importance of building bridges, forming alliances, and collaborating with payers. Panelist would like provide participants a glimpse into the payer world which may have been unseen or unfamiliar to them in their practice. By shifting the current "Us vs. Them" to a collective "We" paradigm, panelist hope to lay a foundation for improved relationships that decrease burdens, improve access, and result in better experiences and outcome for patients.

    Shawn A. Ryan

    MD, MBA, FASAM

    Shawn A. Ryan, MD, MBA is an Dual Board Certified Emergency Physician as well as Addiction Specialist.  He is currently an assistant professor, Department of Emergency Medicine, University of Cincinnati, and President & CMO of BrightView Health.  Dr. Ryan is currently practicing addiction medicine treatment in Cincinnati, is published on this issue, and also serves on many regional, state, and national committees addressing this complicated subject.  Dr. Ryan is President of the Ohio Society of Addiction Medicine and the Chair of Payer-Relations for ASAM and he spends a significant amount of time working with large commercial payers and Medicaid administrators on current and future payment strategies.

    Frank P. James

    MD, JD, FASAM

    Frank P. James, MD, JD, FASAM, FACLM

    Dr. James earned a Bachelor of Arts in Premedical Studies and Japanese Language from the University of Notre Dame.  He earned his Law and Medical Degrees at Southern Illinois University.  Dr. James is a member of both the Ohio and Illinois Bar.  Dr. James is a Veteran of the United States Army, having completed Residency in General Psychiatry at Walther Reed Army Medical Center.  He then completed Fellowships in Child and Adolescent Psychiatry at The Children’s Hospital of Philadelphia and Forensic Psychiatry at the University of Cincinnati School of Medicine.  He is Board Certified in General, Child and Adolescent and Forensic Psychiatry as well as Addiction Medicine.
    Dr. James spent his clinical years providing inpatient and outpatient psychiatric services in underserved areas in the Ohio Valley.  He developed specialty clinics in ADHD, Bipolar Disorder and Schizophrenia, and developed an Opioid Use Disorder (OUD) outpatient clinic focused on the integration of group therapy, psychotropic medication management, and Medication Assisted Treatment (MAT). 
    Dr. James has over five years of experience in managed care with expertise in OUD clinical program development, provider network expansion, and quality improvement measures.  Through participation in peer case discussion, complex case coordination, fraud, waste and abuse investigation, and utilization management, Dr. James provides large behavioral health organizations guidance in drafting evidenced-based benefit guidelines and prior authorizations specific to OUD treatment and MAT.  With an emphasis on understanding member needs, collaborating with providers, and improving payer relations his current passion is medical/behavioral integration and alternative payment models. 
    Dr. James is a member of ASAM’s Finance Committee, Vice Chair of ASAM’s Payer Relations Committee, and Alternate to ASAM’s Board of Directors for Region III.

    Anne C. Fernandez

    MD

    Anne Carroll Fernandez, MD, MS, MBA is the Medical Director for Behavioral Health with Capital District Physicians Health Plan (CDPHP), a regional not for profit, physician run health plan in Upstate New York. She joined CDPHP in December 2012. Prior to joining CDPHP, she practiced psychiatry in the greater Albany Capital District, including over 10 years of direct clinical experience treating patients throughout the rural Leatherstocking Region of New York as an Attending Psychiatrist with Bassett Health Care System in Cooperstown, NY and more recently, as a Staff Psychiatrist with St. Peter’s Addiction Recovery Center in Albany, New York where she worked in a variety of inpatient and outpatient settings.  

    Dr. Fernandez was awarded her MD from State University of New York at Stony Brook, Stony Brook, NY. She completed her medicine internship at the University of Virginia Hospital in Charlottesville, Virginia and, her Psychiatry Residency at Long Island Jewish Medical Center, in Glen Oaks, NY.   She was awarded an M.B.A. in, Health Systems Administration from Union College, an M.S. in Science & Technology Studies from Rensselaer Polytechnic Institute and a B.A. in Biology from Vassar College. 
    Dr. Fernandez is licensed to practice Medicine in New York and is a Diplomate of the American Board of Psychiatry and Neurology and of the American Board of Addiction Medicine. She is a member of the APA and its Executive Committee for the NYS Capital District Branch.  She currently serves on Governor Cuomo’s SUD Treatment and Insurance Workgroup.  Dr. Fernandez is a member of ASAM and serves on its Payers Relations Workgroup
    Prior to attending Medical School, Dr. Fernandez held increasingly responsible positions in healthcare administration and policy as a Senior Budget Examiner with the NYS Division of Budget, Mental Health and Substance Abuse Unit. 

  • Writing Addiction Case Reports for Peer-Reviewed Publications (1 CME)

    Contains 3 Component(s), Includes Credits

    The presenters, editors of ASAM's Journal of Addiction Medicine, aim to provide encouragement and support for addiction specialists to write and submit case reports and to educate trainees.

    Publishing clinical case reports can help communicate new observations and improve clinical care. They also represent scholarship that is do-able for a wide range of addiction clinicians, educators and researchers. Writing a case report is not the same as a clinical research paper nor is it the same as documenting a history and physical. International standards have been developed along with simple checklists to apply them. Journal editors look for the presence of key features in these reports to decide whether they are publishable. In this workshop we will use examples (published, and brought by participants) to discuss international standards by which case reports are evaluated. We will provide guidance regarding how to make it more likely that your case report can be published. The presenters, editors of ASAM's Journal of Addiction Medicine, aim to provide encouragement and support for addiction specialists to write and submit case reports and to educate trainees regarding doing so. As a panel we will entertain questions and answers from the audience. Teaching will be by presentation of standards, group discussion of their application, and review of examples. Attendees are encouraged to send their work in advance or bring it to the workshop. Some will be selected for discussion and critical appraisal. In lieu of those, we will share examples from the literature. During the session we will review case report checklists, apply them to papers, practice developing an outline of content and structure for a case report, and discuss features that make such reports valuable.

    Richard Saitz

    MD, MPH, DFASAM, FACP

    Richard Saitz MD, MPH, FACP, DFASAM is a general internist (DABIM) and primary care physician, an addiction medicine specialist (DABAM), Chair and Professor of Community Health Sciences at Boston University (BU) School of Public Health, and Professor of Medicine at BU School of Medicine. He Chaired the Treatment and Services review committee for the National Institute on Alcohol Abuse and Alcoholism, is Associate Editor of JAMA and Senior Editor of Journal of Addiction Medicine, Section Editor and sole author of key chapters in UpToDate on unhealthy substance use, an editor of the ASAM Principles of Addiction Medicine, and author of >200 peer-reviewed publications http://profiles.bu.edu/display/151440 http://www.bu.edu/sph/profile/richard-saitz/ He was Director of Boston Medical Center’s Clinical Addiction Research and Education (CARE) Unit for over a decade, has been Chairman of an Institutional Review Board, Associate Director of Clinical Research for BU, President of the Association for Medical Education and Research in Substance Abuse (AMERSA), steering committee member of the Motivational Interviewing Network of Trainers (MINT), and was coordinating committee member of International Network for Brief Intervention for Alcohol and other drug problems (INEBRIA). He is Vice President of the International Society of Addiction Journal Editors (ISAJE). His primary areas of expertise supported by NIH, RWJF, and SAMHSA, are screening and brief intervention, integrating substance-related and general health care, improving the quality of care for people with unhealthy substance use, particularly in general health settings, and basing care on science. He validated single-item screening questions recommended by NIDA and NIAAA. Awards: Alpha Omega Alpha Honor Society, Boston Jaycees Ten Outstanding Young Leaders Award, Best Doctors in America®, AMERSA’s W. Anderson Spickard, Jr. Excellence in Mentorship Award, the R. Brinkley Smithers Distinguished Scientist Award (ASAM), Research Society on Alcoholism Distinguished Researcher Award.

    Michael A. Arends

    BSc

    Michael A. Arends, B.Sc., is Senior Research Assistant in the Department of Neuroscience at The Scripps Research Institute, La Jolla, California, where he has worked for the past 20+ years. He graduated in 1995 from the University of California, San Diego, with a bachelor's degree in Psychology. He is currently Managing Editor of Journal of Addiction Medicine (since 2008) and Managing Editor of Pharmacology Biochemistry & Behavior (since 2007). His research interests primarily include drug and alcohol addiction, neuroscience, and neuropsychopharmacology. In 2014, he co-authored the book "Drugs, Addiction and the Brain" with Dr. George Koob and Dr. Michel Le Moal.

    Howard Moss

    MD

    Howard B. Moss, M.D. is Clinical Professor of Psychiatry and Neurosciences at the University of California at Riverside, and Co-Editor of the Journal of Addiction Medicine. He is a board-certified psychiatrist with added qualifications in the subspecialty of Addiction Psychiatry, and is the former Associate Director for Clinical and Translational Research at the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health in Bethesda, Maryland. He has authored over 165 peer-reviewed scientific journal publications and three books. He has been Professor of Psychiatry at University of Pennsylvania, Temple University, and the University of Pittsburgh prior to assuming his role at N.I.H., and has held a Senior Scientist Award from National Institute on Drug Abuse.  His research has focused on the clinical manifestations of substance use disorders, their etiology, and the intergenerational transmission of risk and resilience.  This work has employed diverse methodologies that include psychiatric epidemiology, advanced statistical methods, neurochemistry/neuropharmacology, psychophysiology, biomarker development, neuroimaging, and molecular and behavioral genetics.  Dr. Moss also maintains a private practice of addiction psychiatry in La Jolla, California where he specialized in treating adolescent and adults with problematic involvement with alcohol and drugs, with a special emphasis on abuse of alcohol and prescription opiates. 

    Frank J. Vocci

    PhD

    Frank Vocci, PhD, President and Senior Research Scientist, Friends Research Institute, Baltimore, MD. Following a post-doctoral fellowship in addiction pharmacology at the Medical College of Virginia, Dr. Frank Vocci spent 11 years at the FDA, rising to the level of Chief of the Drug Abuse Staff. At the FDA, he reviewed applications for marketing of medications for analgesic medications and for the treatment of substance abuse disorders. He also participated in domestic and international drug control issues. In 1989, he joined the Medications Development Program at the National Institute on Drug Abuse. He became the Director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC) in 1997 where he was responsible for overseeing research and development activities in medications development for the treatment of addictive disorders. He was also responsible for biomedical research in the medical consequences of drug abuse, primarily AIDS and hepatitis C research. During his tenure, the DPMC collaborated on the development of four addiction drug products that were approved by the FDA. Dr. Vocci has published over 100 articles in neuropharmacology and the treatment of substance abuse and its consequences. In 2001, he received a Meritorious Executive award from President Bush for his management of the NIDA medications development program. Dr. Vocci also received a Distinguished Service Award in 2003 from the College on Problems of Drug Dependence for his contributions to the development of buprenorphine as a treatment for opiate dependence. In 2006 Dr. Vocci received the Vernelle Fox award from the California Society of Addiction Medicine and the FeDerSerD (Italian Addiction Society) award. Dr. Vocci has been a co-editor of the Journal of Addiction Medicine since 2012 and is a past-president of the College on Problems of Drug Dependence.

    Martha J. Wunsch

    MD, FAAP, DFASAM

    Martha J Wunsch, MD, FAAP , DFASAM is an addiction specialist with The Permanente Medical Group in Northern California. She is the Program Director for the Kaiser Addiction Medicine Fellowship and Medical Director of the San Leandro Hospital Addiction Medicine Consultation and Liaiason Service. Marty earned a medical degree at Uniformed Services University of the Health Sciences in Bethesda, Maryland, completed a pediatric internship and residency at Children’s Hospital Los Angeles (1983-1986), and practiced general pediatrics in the Indian Health Service in Arizona.

    Dr. Wunsch was the Hoff Addiction Medicine Fellow at Medical College of Virginia/Virginia Commonwealth University (2000-2002). She is a distinguished fellow of the American Society of Addiction Medicine and a founding co-editor of the Journal of Addiction Medicine. Dr. Wunsch is a founding director of the American Board of Addiction and the President Elect of The Addiction Medicine Foundation.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (2 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    The opening session will focus on the dawn of a new day in addiction medicine with an exciting lineup of ASAM award winners and luminaries in the field.

    Joseph Green A Beacon of Hope: There Are No Lost Causes As a spoken word artist, motivational speaker, and activist for the recovery community, Joseph Green uses poetry interwoven with storytelling to share his battle with addiction and subsequent recovery to deliver a message of inspiration to people who have chosen careers in prevention, intervention, and treatment. Using his own story, Joseph reconnects his audience to the source of their motivation, reminding them that, as important as it is to know what we are fighting against, it is more important to remember what we are fighting for Patrice Harris, MD, MA Sparking Change: The Providers' Role in Combatting the Opioid Crisis Prescription opioid misuse, overdose and death continues to be one of our nation's most complex and challenging public health threats. The American Medical Association and its partner organizations on the Task Force to Reduce Opioid Abuse are working to reverse the epidemic through physician leadership. These efforts include urging physicians to use Prescription Drug Monitoring Programs, enhancing physician education, increasing access to treatment for substance use disorders, promoting comprehensive pain care, including non-opioid and non-pharmacologic care, expanding access to the life-saving drug naloxone, and strengthening state Good Samaritan protections for bystanders who intervene to help overdose patients. As chair of the Task Force, and Board Chair at the AMA, Dr. Patrice Harris will examine key data and policy trends at state and national levels, discuss their effectiveness, and highlight specific efforts still needed to reverse the nation's opioid epidemic. Barbara Mason, PhD Shedding New Light on an Old Problem: Novel Treatments for Alcohol Use Disorder Recent advances in our understanding of the neurobiology of alcohol use disorder can serve as the basis for the development of novel pharmacotherapies. Specifically, the activation of brain stress systems in early abstinence offers pharmacological targets that can be restored to a homeostatic range of functioning and thereby support recovery. Results from clinical trials of novel medications in this domain will be presented, with implications for clinical practice. Vice Admiral Vivek H. Murthy, MD, MBA Facing Addiction: Shining a Spotlight on America's Most Pressing Public Health Issue In his 2016 breakthrough report, US Surgeon General Murthy showed the nation the ubiquitous reach of substance use and addiction in this country. Using staggering data, he defined the public health impact of substance misuse, but also illustrated the tremendous impact that resonates throughout every community. Vice Admiral Vivek H. Murthy will discuss what led to the release of this landmark publication, what the country's next steps will be, and why there is still reason to hope.

    Joseph Green

    Joseph Green is a spoken word artist, educator, and motivational speaker.  Over the past 10 years Joseph’s passion for youth development has led to him supporting young people in a multitude of facets.  He the co-founder and former Program Manager of poetryN.O.W., an after school creative writing program that worked with students throughout the DC metropolitan area.  After five years of successful programming, poetryN.O.W. was acquired by Split This Rock, a Washington DC based poetry and social justice organization, where Joseph now supervises youth programs in over 25 high schools.  In his work with poetryN.O.W. and Split This Rock, Joseph has also crafted an extensive creative writing curriculum now used in classrooms throughout the country.

    In his prevention work with high schooled aged youth, Joseph facilitates interactive workshops to create transformational original poems on the effects that substance abuse and addiction has had on their lives. By empowering students to speak truth to power, Joseph has provided opportunities for them to share their stories with policy makers at the White House for the US Office of National Drug Control Policy and the US Department of Education. In his role as Program Manager at the Mentor Foundation USA, Joseph led the effort to revamp the interactive drug prevention youth rally known as Shattering the Myths.  As part of this initiative, he also served as host for the three day program that included a full day of writing workshops and leadership training.
    2015 marked Joseph’s fifth return to Poetry Slam International’s national slam, this time as a representative of the DC Poetry Slam Team. He represented the Oneonta slam team in 2005 and 2006 as their Grand Slam Champion, Slam Richmond in 2009, and DC’s Beltway Poetry Slam team in 2011. He also represented DC in 2011 at the Individual Poetry Slam, ranking 16th in the world. As a solo artist, Joseph has performed, hosted, and featured at venues and schools throughout the United States, including the White House and Kennedy Center. He has over ten years experience as a professional spoken word artist and writer.
    Joseph believes in the power of using lived experiences to catalyze positive personal change, and often pulls from his own unique set of experiences to engage groups of all ages and backgrounds. In 2012 he started the interactive performance series, Dive Every Day Project, with the intent of opening dialogue around the topic of substance use disorder, addiction, and recovery. The Dive Every Day Project pulls from a catalog of original work dealing directly with these issues, drawing from personal and family experiences. Dive Every Day serves to be a tool of inspiration and guidance for all who encounter it and is a testament to self-forgiveness, redemption, and the irreplaceable role of love in the human revolution.

    Patrice A. Harris

    MD, MA

    Dr. Patrice Harris, a psychiatrist from Atlanta, is chair of the American Medical Association’s (AMA) Board of Trustees.

    Active in organized medicine her entire career, Dr. Harris has held many leadership positions at both the national and state level.  In addition to serving on the AMA’s Board of Trustees since 2011, Dr. Harris previously served as chair of the AMA’s Council on Legislation, and on the boards of the American Psychiatric Association and the Georgia Psychiatric Physicians Association.
    As past director of Health Services for Fulton County, Georgia, which includes Atlanta, Dr. Harris oversaw all county health-related programs and functions, and spearheaded the county’s efforts to integrate public health, behavioral health and primary care services.
    Governing themes in Dr. Harris’ professional life are a passion to improve the lives of children and service to others, and she has worked for children both clinically and in the advocacy arena.
    A key focus for Dr. Harris currently is developing solutions to end the nation’s opioid epidemic.  She is chair of the AMA’s Task Force to Reduce Opioid Abuse, which brings together specialty and state medical societies and other health care associations to move swiftly to implement best practices to combat the opioid epidemic and save lives.

    Barbara Mason

    PhD

    Barbara J. Mason, Ph.D. is the Pearson Family Professor, Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Acting Chair of the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of alcohol use disorders has been recognized with a MERIT Award from the National Institutes of Health (NIH), the Dean's Senior Clinical Research Award from the University of Miami School of Medicine, and the Andrew W. Mellon Foundation Teacher-Scientist Award from Cornell University Medical College. Dr. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence; nalmefene (Selincro) has recently received regulatory approval for the treatment of alcohol dependence in the European Union. Dr. Mason also served as overall Principal Investigator for the US multicenter trial of acamprosate (Campral) for the treatment of alcohol dependence which was conducted in support of FDA approval. Dr. Mason has served on the National Advisory Councils of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Advisory Council of the National Institute on Drug Abuse (NIDA). Dr. Mason is an elected Fellow of the American College of Neuropsychopharmacology and has held multiple editorial positions, including serving as a current member of the editorial board for the Journal of Addiction Medicine. Dr. Mason holds the Pearson Family Chair, an endowed position in alcohol and addiction research at The Scripps Research Institute, and is currently conducting a program of NIH-funded research that includes human laboratory studies to screen medications for therapeutic potential for alcohol dependence and clinical trials to evaluate the safety and efficacy of novel medications for alcohol and cannabis dependence.

    Vivek H. Murthy

    Vice Admiral, MD, MBA

    Vice Admiral (VADM) Vivek H. Murthy, M.D., M.B.A., was nominated by President Barack Obama in November 2013 and confirmed on December 15, 2014 as the 19th United States Surgeon General. As America’s Doctor, Dr. Murthy is responsible for communicating the best available scientific information to the public regarding ways to improve personal health and the health of the nation. He also oversees the operations of the U.S. Public Health Service (USPHS) Commissioned Corps, comprised of approximately 6,700 uniformed health officers who serve in locations around the world to promote, protect, and advance the health and safety of our nation. 

    Dr. Murthy has devoted himself to improving public health through the lens of service, clinical care, research, education, and entrepreneurship. The son of immigrants from India, Dr. Murthy discovered a love for the art of healing early in his childhood while spending time in his father’s medical clinic in Miami, Florida. After attending Miami Palmetto Senior High School, he received his Bachelor’s degree from Harvard, and his M.D. and M.B.A. degrees from Yale. He completed his residency training at Brigham and Women’s Hospital and Harvard Medical School where he later joined the faculty as an internal medicine physician and instructor. As a clinician-educator, Dr. Murthy has cared for thousands of patients and trained hundreds of residents and medical students. He regards caring for patients as the greatest privilege of his life.  
    In addition to clinical practice, Dr. Murthy has two decades of experience and perspective improving health in communities across the country and around the world. He co-founded VISIONS, an HIV/AIDS education program in India and the United States, which he led for eight years. As its president, he established ten chapters with hundreds of volunteers in both countries and grew the organization’s education programs to reach more than 45,000 youth. Dr. Murthy also co-founded the Swasthya project (“health and wellbeing” in Sanskrit), a community health partnership in rural India, to train women to be health providers and educators. During his five-year tenure with the organization, he established seed funding and helped expand research and direct care programs that reached tens of thousands of rural residents.
    As a research scientist, Dr. Murthy has conducted laboratory research on vaccine development and studied the participation of women and minorities in clinical trials. His research findings have been published in Science, the Journal of the American Medical Association, and the Journal of the National Cancer Institute. Dr. Murthy is also a healthcare entrepreneur and innovator. He co-founded and chaired a successful software technology company, TrialNetworks, which improves research collaboration and enhances the efficiency of clinical trials around the world. In seven years, Dr. Murthy and his team took the company from conception to an international enterprise that powers dozens of clinical trials for over 50,000 patients in more than 75 countries. Dr. Murthy has also served as the president of Doctors for America, a non-profit organization with more than 16,000 physicians and medical students in all 50 states who work with patients and policymakers to build a high quality, affordable health system for all.
    Seen by many as a proven leader who can use 21st century approaches and technology to modernize the role of Surgeon General, Dr. Murthy will focus his efforts on building cross-sector partnerships in communities to address the epidemics of obesity and tobacco-related disease, to reduce the stigma associated with mental illness, to improve vaccination rates, and to make prevention and health promotion the backbone of our communities. Dr. Murthy firmly believes that our nation's greatest strength has always come from its people. Improving the health of our people means strengthening our communities and our country. That will be Dr. Murthy’s highest priority as Surgeon General. 

  • Addiction 60/60: All of Addiction Medicine in 60 Slides and 60 Minutes (1.5 CME)

    Contains 3 Component(s), Includes Credits

    This session offers an ultra-fast-paced, “state-of-the-art” review of 2017 Addiction Medicine in the context of our current understanding of the addictive process. We will review how current neurobiology approaches craving and control, and how these novel concepts inform our treatment options, both pharmacological and psychosocial.

    Addiction specialists these days do much more than treat patients. Educating people about addiction and helping them understand the disease from a medical perspective is a ubiquitous request. From giving a Grand Rounds presentation to seasoned attending physicians to training hospital staff through in-service programs to responding to the media, we are often called on to talk about addiction and its treatments. In this workshop, we will attempt to refine a one-hour PowerPoint lecture that covers the essentials of Addiction Medicine in 2017. We will strictly use 60 slides with no more than 60 words per slide to deliver the lecture. The first part, the Fundamentals of Addiction Medicine will cover (1) the Neurobiology of Addiction; (2) Alcohol; (3) Sedatives; (4) Opioids; (5) Stimulants; (6) Nicotine; (7) Cannabis; (8) Dissociatives, Hallucinogens, and Steroids; and (9) the Behavioral Addictions. The second part, Assessments and Treatments will address (1) the Epidemiology of Addiction; (2) Public Policy; (3) Screening, Brief Intervention, and Referral to Treatment (SBIRT), ASAM Patient Placement Criteria (PPC), and other Assessment Tools; (4) Toxicology Examinations; (5) 12-Step Programs; (6) Cognitive Behavior Therapy; (7) Motivational Interviewing; (8) Medical Co-Morbidities; and (9) Psychiatric Co-Morbidities. Finally, the third part, Special Populations and Topics will look into (1) Pain and Addiction; (2) Maternal/Child Issues; (3) Adolescents; (4) the Elderly; (5) Impaired Professionals; and (6) the Future of Addiction Medicine. This 24-part review of our field can also serve as a basic template for the development of full-day or multiple-day courses in Addiction Medicine. During the second hour of the workshop, the presenters will invite participants to critique the presentation; change, add, or delete topics and slides; and discuss the usefulness of such an admittedly ambitious undertaking. This is the second time that we will try this approach-- the first time we attempted the 60/60 was at the 2013 ASAM Med-Sci Conference in Chicago. We have refined the presentation since then, based on feedback we have received from students, trainees, and fellow addiction specialists.

    Petros Levounis

    MD, MA, DFASAM

    Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he received an MA degree in sociology from Stanford before moving to New York City where he trained in psychiatry at Columbia University. He graduated from Columbia receiving the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University. From 2002 to 2013, he served as director of the Addiction Institute of New York.
    Dr. Levounis has written numerous articles and monographs; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by all major television networks. Dr. Levounis serves on the Board of Directors of the American Society of Addiction Medicine (ASAM) and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association. Dr. Levounis is a Betty Ford Scholar, a recipient of a U.S. State Department Speaker and Specialist Award, a distinguished fellow of the APA and ASAM, and an honorary member of the World Psychiatric Association. 

    Dr. Levounis has published thirteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “The Behavioral Addictions,” “Motivational Interviewing for Clinical Practice,” “Becoming Mindful,” and the “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition. His books have been translated into German, Hungarian, Japanese, Portuguese, and Spanish. 

    Dr. Levounis is married to actor Lukas Hassel and lives in New York City.

  • National Perspectives Plenary (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This lively session will give attendees the opportunity to interact with representatives from SAMHSA, NIAAA, and NIDA.

    The National Perspectives Plenary Session is new this year and was created to provide the opportunity for leaders of federal agencies to address emerging issues and advances in addiction medicine with short, pointed presentations. Attendees will have the opportunity to ask questions of agency leaders during the last half of the session. Moderated by ASAM President, R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM and Annual Conference Program Planning Committee Chair, Michael Fingerhood MD, FACP, this lively session will give attendees the opportunity to interact with representatives from SAMHSA, NIAAA, and NIDA.

    Kana Enomoto

    MA

    Ms. Enomoto has been delegated—by the Department of Health and Human Services Secretary Sylvia M Burwell—the functions, duties, and authorities of the Administrator to oversee an agency with four centers, four offices, over 600 employees, and a budget of $3.7 billion. Through data, policy, public education, and grants, Ms. Enomoto and the SAMHSA team advance the agency's mission to reduce the impact of substance abuse and mental illness on America's communities. Ms. Enomoto has served as Principal Deputy Administrator and principal advisor to the SAMHSA Administrator on operations, policies, and programmatic activities for the agency since August 2011. Prior to that, Ms. Enomoto served as the Director of the Office of Policy, Planning, and Innovation, where she developed, coordinated, and communicated SAMHSA policies across the full spectrum of mental health and substance abuse issues. From 2005-2009, Ms. Enomoto served as the Principal Senior Advisor to three SAMHSA Administrators, and as the Acting Deputy Administrator between 2008 and 2009. She began her tenure at SAMHSA in 1998 as a Presidential Management Fellow. She began her career in research and clinical services with a focus on minority mental health and trauma. Ms. Enomoto has received awards in recognition of her work, including the Arthur S. Flemming Award, the American College of Mental Health Administration King Davis Award, and the Secretary's Award for Distinguished Service. Ms. Enomoto earned her bachelor's degree in psychology and master's degree in clinical psychology from the University of California, Los Angeles and is a graduate of Harvard University's Kennedy School of Government, Senior Managers in Government Program.

    George F. Koob

    PhD

    George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 650 peer reviewed papers and several books including the “Neurobiology of Addiction," a comprehensive treatise on emerging research in the field. He has mentored 11 PhD students and over 75 post-doctoral fellows.

    Wilson Compton

    MD, MPE

    Dr. Wilson M. Compton serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.